CliffBio
small molecule

ACETAMINOPHEN

ACETAMINOPHEN

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameACETAMINOPHEN
Active ingredientACETAMINOPHEN
Strength120MG
Dosage formSUPPOSITORY
RouteRECTAL
ModalitySmall molecule
FDA approvalSeptember 1983
Marketing statusOTC

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.